Ojemda® (tasurgratinib)
Pediatric cancers with NTRK fusions
Regulatory ReviewPositive CHMP opinion received
Key Facts
Indication
Pediatric cancers with NTRK fusions
Phase
Regulatory Review
Status
Positive CHMP opinion received
Company
About Ipsen
Ipsen is a global specialty-care biopharmaceutical company with a focused mission to develop and commercialize innovative medicines in oncology, rare diseases, and neuroscience. Under CEO David Loew, the company has achieved strong commercial execution, delivering over 9% sales growth in 2024 and upgrading guidance in 2025, underpinned by a robust balance sheet and investment-grade credit ratings. Its strategy centers on deep therapeutic area specialization, a balanced internal and external innovation model, and leveraging its unique toxin platform to build a sustainable, high-growth pipeline.
View full company profile